The Online Investor



Gyre Therapeutics Inc (CBIO)

Catalyst Biosciences, together with its subsidiary, is a biopharmaceutical company focused on development and commercialization of Hydronidone for the treatment of NASH (nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease) in the U.S. Hydronidone is being evaluated for the treatment of liver fibrosis associated with a spectrum of chronic liver diseases. A Phase 1 clinical trial of Hydronidone has been completed in the U.S. and generated pharmacokinetic, safety and tolerability data of single and multiple ascending doses of Hydronidone in U.S. healthy subjects.
Company Name: 
Gyre Therapeutics Inc
Website: 
www.catalystbiosciences.com
Sector: 
Biotechnology
Quotes delayed 20 minutes

Email EnvelopeFree CBIO Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)

Analysts' Target Price:
CBIO Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Gyre Therapeutics Inc (CBIO) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.